---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-24-000136"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:23:02.891281+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioMarin enters $600M revolving credit facility maturing 2029, undrawn at closing

## Summary
- Entered $600M revolving credit facility with Citibank as administrative agent.
- Facility matures on August 28, 2029; no amounts drawn at closing.
- Interest: Term SOFR plus 112.5-175 bps or Base Rate plus 12.5-75 bps, based on leverage.
- Proceeds to finance working capital and general corporate purposes.
- Includes customary covenants restricting debt, liens, investments, and dividends.

## SEC filing metadata
- accession: 0001048477-24-000136
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000136/0001048477-24-000136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000136/bmrn-20240828.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-24-000136
- JSON: https://secwatch.observer/filing/0001048477-24-000136.json
- Plain text: https://secwatch.observer/filing/0001048477-24-000136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.